News | December 17, 2023
Biocon Biologics recognized as an Asia IP Elite for 2023
Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list
Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
The company has raised US$4.5 million in funding for its AI operating system
Dr. Reddy’s maintains that the allegations against it lack merit and will vigorously defend the litigation
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
Lokavant provides clinical trial intelligence
Capital raise to accelerate product and technology development and support expansion efforts to reshape communications to HCPs across the globe
The investment will help the company meet soaring demand for user-friendly oral dosage form development and manufacturing
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
Subscribe To Our Newsletter & Stay Updated
